Double punch: HPV vaccine plus immunotherapy before standard care for throat cancer
NCT ID NCT05996523
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 25 times
Summary
This study tests whether giving an HPV vaccine (PRGN-2009) together with the immunotherapy drug pembrolizumab before standard treatment can boost the immune system's attack on HPV-positive oropharyngeal cancer. About 16 adults with newly diagnosed, advanced-stage disease will receive the combination over a few weeks, then proceed to standard therapy. The main goal is to see if this approach increases cancer-fighting immune cells in the tumor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OROPHARYNGEAL SQUAMOUS CELL CARCINOMA (SCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.